Gene therapy for cholesterol: Initial test results cheer

A new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in bad cholesterol. This one-time infusion could transform heart disease management. Larger trials are planned, with a Phase II trial starting soon. This approach may eventually benefit broader populations at high cardiovascular risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C6LDpzy
via IFTTT